HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries
Sheela Upadhyaya and
Health Policy, 2019, vol. 123, issue 2, 140-151
Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to specifically address issues related to HTA of OMPs.
Keywords: Rare diseases; Technology assessment; Value of life; England; Scotland; Europe; Uncertainty (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:2:p:140-151
Access Statistics for this article
Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput
More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Dana Niculescu ().